SynthesisPloS one2013
Post-mastectomy radiotherapy for breast cancer patients with t1-t2 and 1-3 positive lymph nodes: a meta-analysis.
Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Can radiotherapy be omitted in T1-2N1 breast cancer patients after mastectomy without neoadjuvant therapy?Frontiers in oncology · 2025Pooled it
- Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes.The Cochrane database of systematic reviews · 2023Pooled it
- DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Guideline
- Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis.Breast cancer research and treatment · 2026Article
- Postmastectomy Radiation Therapy: An ASTRO/ASCO/SSO Clinical Practice Guideline.Annals of surgical oncology · 2025Article
- The significance of risk stratification through nomogram-based assessment in determining postmastectomy radiotherapy for patients diagnosed with pTRadiation oncology (London, England) · 2024Article
- Retrospective evaluation of the contribution of radiotherapy to survival in breast cancer treatment with propensity score based on stage and subgroup.Radiation oncology (London, England) · 2024Article
- Factors associated with alteration of nipple or skin sensation and impact of duration of time following nipple-sparing mastectomy (NSM): an analysis of 460 cases with comparison of conventional versus endoscopic- or robotic-assisted NSM.World journal of surgical oncology · 2023Article
- Article
- Correlation of dynamic contrast-enhanced MRI and diffusion-weighted MR imaging with prognostic factors and subtypes of breast cancers.Frontiers in oncology · 2022Article
- Occult breast cancer: Where are we at?Breast (Edinburgh, Scotland) · 2020Review
- The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype.Breast (Edinburgh, Scotland) · 2020Article
- When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?Current oncology reports · 2019Review
- Personalized radiotherapy for invasive breast cancer in 2017 : National S3 guidelines and DEGRO and AGO recommendations.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017Article
- Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.OncoTargets and therapy · 2017Review
- Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients.BMC cancer · 2016Article
- Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Observational
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Breast care (Basel, Switzerland) · 2014Article
- LINC01140 Hinders the Development of Breast Cancer Through Targeting miR-200b-3p to Downregulate DMD.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of post-mastectomy radiotherapy (PMRT) in patients with T1-2 and 1-3 positive lymph nodes remains controversial. The aim of this study is to investigate the possible benefits of PMRT for this subgroup.
methodsThree electronic databases were systematically quarried (Cochrane Library, MEDLINE, and EMBASE) for published studies evaluating the effects of PMRT on breast cancer patients with T1-T2 tumors with 1-3 positive lymph nodes. Of the 334 studies identified, information was available for 3432 patients from 10 clinical studies. Pooled relative risk estimates (RR) and overall survival (OS) were calculated using the inverse variance weighted approach, publication bias and chi-square test were also calculated.
resultsFrom the 10 studies, the pooled RR (RRs) for locoregional recurrence (LRR) with PMRT was 0.348 (95% CI = 0.254 to 0.477), suggesting a significant benefit for PMRT to decrease the risk of LRR in patients with T1-T2 tumors and 1-3 positive nodes (p<0.05). Reporting bias ( Begg's p = 0.152; Egger's p = 0.107) or significant heterogeneity (Cochran's p = 0.380; I(2) = 6.7%) were not detected. For further subset analysis, the RR for T1, N1-3+ tumors was 0.330 (95% CI = 0.171 to 0.639); for T2, N1-3+ tumors the RR was 0.226 (95% CI = 0.121 to 0.424). The pooled RR for overall survival (OS) was not significantly different between PMRT and no-PMRT group (1.051, 95% CI =1.001 to 1.104).
conclusionsOur pooled analysis revealed that PMRT significantly reduces the risk of LRR in patients with TI-T2 tumors with 1-3 positive nodes, and the magnitude of the LRR risk reduction is slightly greater for larger tumors. Our results suggest that PMRT should be considered for patients with T1/T2 tumors with 1-3 positive nodes to decrease the relatively high risk of LRR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.